1. Effect of treatment on carbohydrate metabolism and skeletal and pubertal maturation
GH dose
12 months of treatment
24 months of treatment
Low
Medium
High
Low
Medium
High
Fasting plasma glucose (mg/dl)
83±15
81±17
85±11
87±17
86±17
85±16
Fasting insulin (µU/ml)
9±6
13±9
15±11
13±9
13±8
17±10
HbA1c (%)
5.4±0.6
5.3±0.4
5.3±0.5
5.2±0.7
5.2±0.5
5.3±0.4
Mean bone age delay
2.9±1.2
2.5±1.4
2.3±1.5
2.8±1.1
2.7±1.4
2.0±1.0
Bone age advancement (during preceding year)
0.7±0.7
1.2±1.0
1.2±0.9
0.8±0.6
0.7±1.2
1.0±0.8
Patients in puberty (n)
21% (7)
10% (4)
16% (4)
24% (8)
30% (11)
29% (10)
Girls in puberty (n)
22% (2)
7% (1)
30% (3)
33% (3)
29% (4)
40% (4)
Boys in puberty (n)
20% (5)
13% (3)
4% (1)
20% (5)
30% (7)
25% (6)
With the exception of fasting insulin, no significant differences among these parameters were observed as a function of dose, gender or length of treatment
Abbildung mod. nach Cohen, 2002